PAXLOVID™ (nirmatrelvir; ritonavir) is authorised in GEORGIA

On February 24, 2022 the LEPL Regulation Agency for Medical and Pharmaceutical Activities of the Ministry of Internally Displaced Persons from Occupied Territories, Labour, Health and Social Affairs of Georgia has granted Emergency Use Authorization for PAXLOVID™ for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

Read the PAXLOVID™ Package Leaflet: Information for the Patient

Ensuring the Authenticity of PAXLOVID™

Authentic PAXLOVID™ from Pfizer will include the Pfizer name on the carton. Paxlovid tablets are available in 5 daily-dose blister cards with a total of 30 tablets packaged in a carton. Each daily blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each) and indicates which tablets need to be taken in the morning and evening. Nirmatrelvir 150 mg film-coated tablets are pink, oval-shaped and debossed with ‘PFE’ on one side and ‘3CL’ on the other side. Ritonavir 100 mg film-coated tablets are white to off white, capsule shaped and debossed with ‘H’ on one side and ‘R9’ on the other side.

The flaps at each end of the carton are glued as a tamper evident feature of the packaging.

The outer carton of the box has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.

If you suspect the PAXLOVID™ you have received may be counterfeit, please report this e-mail caucar_pgs@pfizer.com. To learn more, visit https://www.pfizer.com/counterfeiting/frequently-asked-questions